Data from the phase 3 PACIFIC trial for patients with stage III locally advanced and unresectable non-small cell lung cancer that had not progressed after ≥2 cycles of chemoradiation revealed that the addition of consolidation durvalumab (anti-PD-L1 monoclonal antibody) significantly improved PFS and OS over placebo [98,99]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.